Skip to main navigation
Skip to main content
Skip to Footer
Global
Novartis Site Directory
Our Services
Assay Development for Intended Use
Clinical Trial Testing
Companion Diagnostics Solutions
Partnership Opportunitites
Portfolio
Our Company
Who We Are
Leadership
Join Us
Contact
Our Capabilities
Technical
Project Management
Data Management
Global Logistics
Portfolio
Lab Partnerships
Companion Diagnostics Partners
Service Inquiries
Our Experience
Navigate Team
Publications
Services Metrics
Quality
Search
News Archive
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Featured News
Media Releases
In the News
Stories
Filter By
2020
March
Story
/
Mar 20, 2020
Coronavirus (COVID-19) Impact Notification
Read More
2016
October
Media Release
/
Oct 24, 2016
Test Media Release
Test Media ReleaseTest Media ReleaseTest Media ReleaseTest Media ReleaseTest Media Release
Read More
2015
October
Media Release
/
Oct 02, 2015
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
Read More
September
Media Release
/
Sep 30, 2015
Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
Read More
Media Release
/
Sep 28, 2015
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
Read More
Media Release
/
Sep 27, 2015
Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET
Read More
Media Release
/
Sep 25, 2015
Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval
Read More
Media Release
/
Sep 24, 2015
Read More
Media Release
/
Sep 24, 2015
Read More
Media Release
/
Sep 24, 2015
Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
Print
Save
You are here
Home
›